A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

This phase II, single-arm, multicenter study examined the efficacy and safety of coltuximab ravtansine (an anti-CD19 antibody drug conjugate) in 61 patients with histologically documented (de novo or transformed) relapsed or refractory diffuse large B-cell lymphoma who had previously received rituxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Trnĕný, Marek, Verhoef, Gregor, Dyer, Martin JS, Ben Yehuda, Dina, Patti, Caterina, Canales, Miguel, Lopez, Andrés, Awan, Farrukh T, Montgomery, Paul G, Janikova, Andrea, Barbui, Anna M, Sulek, Kazimierz, Terol, Maria J, Radford, John, Guidetti, Anna, Di Nicola, Massimo, Siraudin, Laure, Hatteville, Laurence, Schwab, Sandrine, Oprea, Corina, Gianni, Alessandro M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068033/
https://www.ncbi.nlm.nih.gov/pubmed/29748443
http://dx.doi.org/10.3324/haematol.2017.168401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068033/
https://www.ncbi.nlm.nih.gov/pubmed/29748443
http://dx.doi.org/10.3324/haematol.2017.168401

Ejemplares similares